In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers.
Animals
Antineoplastic Agents
/ chemical synthesis
Brain Neoplasms
/ genetics
Carbocyanines
/ chemistry
Cell Cycle Proteins
/ antagonists & inhibitors
Cell Line, Tumor
Drug Carriers
/ chemical synthesis
Fluorescent Dyes
/ chemistry
Gene Expression Regulation, Neoplastic
Humans
Injections, Intravenous
Male
Mice
Nanostructures
/ administration & dosage
Oligonucleotides
/ chemical synthesis
Pancreatic Neoplasms
/ genetics
Polyethylene Glycols
/ chemistry
Polylysine
/ chemistry
Protein Serine-Threonine Kinases
/ antagonists & inhibitors
Proto-Oncogene Proteins
/ antagonists & inhibitors
RNA, Long Noncoding
/ antagonists & inhibitors
RNA, Small Interfering
/ chemical synthesis
Static Electricity
Survival Analysis
Xenograft Model Antitumor Assays
Polo-Like Kinase 1
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
24 04 2019
24 04 2019
Historique:
received:
17
12
2018
accepted:
29
03
2019
entrez:
26
4
2019
pubmed:
26
4
2019
medline:
9
5
2019
Statut:
epublish
Résumé
Stabilisation of fragile oligonucleotides, typically small interfering RNA (siRNA), is one of the most critical issues for oligonucleotide therapeutics. Many previous studies encapsulated oligonucleotides into ~100-nm nanoparticles. However, such nanoparticles inevitably accumulate in liver and spleen. Further, some intractable cancers, e.g., tumours in pancreas and brain, have inherent barrier characteristics preventing the penetration of such nanoparticles into tumour microenvironments. Herein, we report an alternative approach to cancer-targeted oligonucleotide delivery using a Y-shaped block catiomer (YBC) with precisely regulated chain length. Notably, the number of positive charges in YBC is adjusted to match that of negative charges in each oligonucleotide strand (i.e., 20). The YBC rendezvouses with a single oligonucleotide in the bloodstream to generate a dynamic ion-pair, termed unit polyion complex (uPIC). Owing to both significant longevity in the bloodstream and appreciably small size (~18 nm), the uPIC efficiently delivers oligonucleotides into pancreatic tumour and brain tumour models, exerting significant antitumour activity.
Identifiants
pubmed: 31019193
doi: 10.1038/s41467-019-09856-w
pii: 10.1038/s41467-019-09856-w
pmc: PMC6482185
doi:
Substances chimiques
Alexa Fluor 647
0
Antineoplastic Agents
0
Carbocyanines
0
Cell Cycle Proteins
0
Drug Carriers
0
Fluorescent Dyes
0
Oligonucleotides
0
Proto-Oncogene Proteins
0
RNA, Long Noncoding
0
RNA, Small Interfering
0
TUG1 long noncoding RNA, human
0
Polylysine
25104-18-1
Polyethylene Glycols
3WJQ0SDW1A
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1894Références
Nat Rev Cancer. 2006 Apr;6(4):321-30
pubmed: 16557283
J Natl Cancer Inst. 2006 Mar 1;98(5):335-44
pubmed: 16507830
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3460-5
pubmed: 17307870
Nature. 2001 May 24;411(6836):494-8
pubmed: 11373684
Nat Rev Drug Discov. 2012 Jan 20;11(2):125-40
pubmed: 22262036
Science. 1988 Apr 8;240(4849):177-84
pubmed: 2451290
Adv Drug Deliv Rev. 2015 Aug 30;91:3-6
pubmed: 25579058
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):11397-402
pubmed: 23801758
Pharmacol Ther. 2016 Jul;163:94-108
pubmed: 27063403
Macromol Rapid Commun. 2016 Mar;37(6):486-93
pubmed: 26765970
Adv Drug Deliv Rev. 2001 Mar 23;47(1):113-31
pubmed: 11251249
Nat Commun. 2016 Dec 06;7:13616
pubmed: 27922002
Biomaterials. 2016 Jun;90:62-71
pubmed: 26986857
PLoS One. 2011;6(10):e26221
pubmed: 22028836
Biophys J. 2000 Mar;78(3):1606-19
pubmed: 10692345
Oncology. 2005;69 Suppl 3:11-6
pubmed: 16301831
J Am Chem Soc. 2013 Jan 30;135(4):1423-9
pubmed: 23289646
J Clin Invest. 2009 Mar;119(3):661-73
pubmed: 19229107
Mol Immunol. 1985 Mar;22(3):161-206
pubmed: 3889592
Pancreas. 2010 May;39(4):425-35
pubmed: 20418756
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Biomacromolecules. 2011 Sep 12;12(9):3174-85
pubmed: 21863796
Cancer Res. 2015 Apr 1;75(7):1356-65
pubmed: 25627979
Nat Commun. 2011 Jul 19;2:395
pubmed: 21772266
Cancer Res. 2004 May 15;64(10):3365-70
pubmed: 15150085
Nat Nanotechnol. 2011 Oct 23;6(12):815-23
pubmed: 22020122
Science. 1999 Jan 1;283(5398):65-7
pubmed: 9872741
Nat Biotechnol. 2010 Feb;28(2):172-6
pubmed: 20081866
Nat Rev Genet. 2015 Sep;16(9):543-52
pubmed: 26281785
Analyst. 2014 Jan 7;139(1):79-92
pubmed: 24244936
Macromol Rapid Commun. 2010 Jul 1;31(13):1181-6
pubmed: 21590873
Clin Cancer Res. 2007 Mar 15;13(6):1663-74
pubmed: 17363519
Clin Cancer Res. 2009 Aug 1;15(15):4915-24
pubmed: 19622581
Nat Mater. 2013 Nov;12(11):967-77
pubmed: 24150415
Nat Biotechnol. 2011 Oct 09;29(11):1005-10
pubmed: 21983520
Biomed Opt Express. 2010 Oct 21;1(4):1209-1216
pubmed: 21258542
J Control Release. 2016 May 28;230:109-15
pubmed: 27080571
ACS Nano. 2013 Oct 22;7(10):8583-92
pubmed: 24028526